


## SARS-CoV-2-IN-27

Cat. No.:	HY-151271
Molecular Formula:	C <sub>54</sub> H <sub>56</sub> O <sub>8</sub> P <sub>2</sub>
Molecular Weight:	894.97
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC <sub>50</sub> s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC <sub>50</sub> value of 6.5 μM <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 6.5 μM (viral liposome, SARS-CoV-2) <sup>[1]</sup>								
<b>In Vitro</b>	<p>SARS-CoV-2-IN-27 (CP019) inhibits SARS-CoV-2 (IC<sub>50</sub>=1.7 μM) with few cytotoxicity (Caco2 cells, CC<sub>50</sub>=208 μM)<sup>[1]</sup>. SARS-CoV-2-IN-27 (0-15 μM; 2 h) inactivate SARS-CoV-2, shows inhibition against infection with an IC<sub>50</sub> value of 1.0 μM<sup>[1]</sup>. SARS-CoV-2-IN-27 suppresses various enveloped viruses activity with IC<sub>50</sub>s of 7.4 μM (respiratory syncytial virus, RSV), 112.6 μM (influenza A virus, IAV), 4.6 μM (measles virus, MeV), 1.8 μM (herpes simplex viruses, HSV-1), respectively<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Caco2 cells exposed with SARS-CoV-2 (2 h, 37 °C)</td> </tr> <tr> <td>Concentration:</td> <td>0, 0.23, 0.93, 3.75, 15 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>2 hours; determined infection rates on day 2</td> </tr> <tr> <td>Result:</td> <td>Inhibited SARS-CoV-2 infection activity to Caco2 cells.</td> </tr> </table>	Cell Line:	Caco2 cells exposed with SARS-CoV-2 (2 h, 37 °C)	Concentration:	0, 0.23, 0.93, 3.75, 15 μM	Incubation Time:	2 hours; determined infection rates on day 2	Result:	Inhibited SARS-CoV-2 infection activity to Caco2 cells.
Cell Line:	Caco2 cells exposed with SARS-CoV-2 (2 h, 37 °C)								
Concentration:	0, 0.23, 0.93, 3.75, 15 μM								
Incubation Time:	2 hours; determined infection rates on day 2								
Result:	Inhibited SARS-CoV-2 infection activity to Caco2 cells.								
<b>In Vivo</b>	<p>SARS-CoV-2-IN-27 (CP019) (150 μM, 50 μL; intranasal route; for 2-5 d) shows antiviral activity in vivo against respiratory syncytial virus (RSV) and SARS-CoV-2 in BALB/cJ mice or K18-hACE2 mice, respectively<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Respiratory syncytial virus (RSV) infection of BALB/cJ mice and SARS-CoV-2 infection of K18-hACE2 mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>150 μM, 50 μL</td> </tr> <tr> <td>Administration:</td> <td>Intranasal route; single dose; sacrificed BALB/cJ mice on day 5; treated K18-hACE2 mice once again after 7 h and sacrificed mice on day 2</td> </tr> </table>	Animal Model:	Respiratory syncytial virus (RSV) infection of BALB/cJ mice and SARS-CoV-2 infection of K18-hACE2 mice <sup>[1]</sup>	Dosage:	150 μM, 50 μL	Administration:	Intranasal route; single dose; sacrificed BALB/cJ mice on day 5; treated K18-hACE2 mice once again after 7 h and sacrificed mice on day 2		
Animal Model:	Respiratory syncytial virus (RSV) infection of BALB/cJ mice and SARS-CoV-2 infection of K18-hACE2 mice <sup>[1]</sup>								
Dosage:	150 μM, 50 μL								
Administration:	Intranasal route; single dose; sacrificed BALB/cJ mice on day 5; treated K18-hACE2 mice once again after 7 h and sacrificed mice on day 2								

---

Result:	Reduced viral load in the lungs of SARS-CoV-2-infected mice. Completely abolished SARS-CoV-2 infection of all tested mice without changing body weight of mice.
---------	--

---

## REFERENCES

[1]. Tatjana Weil, et al. Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses. JACS Au 2022, XXXX, XXX, XXX-XXX.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA